KRAS and colorectal carcinoma: Moreover, HK enhances cetuximab sensitivity in KRAS-mutant CRC preclinical model by destabilizing the SNX3 retromer complex [7], and semisynthetic honokiol thioethers have shown potent activity against HCT116 CRC cells through inhibition of YAP transcription and expression [11].